Table 1.

Univariable Analysis for the Summary of Demographics and Baseline Characteristics of 232 RA Patients.

		Remission (Group A)	No remission (Group B)	p
n		164	68
Age (years)		54.8 ± 15.2	61.8 ± 13.3	0.001*
Sex (female: male)		138:26	55:13	0.680**
Bio-naive or Switch		121:43	38:29	0.017**
Disease duration (year)		7.1 ± 11.1	9.1 ± 8.5	0.031*
Steroid dosage (mg/d)		3.4 ± 3.7	4.5 ± 3.5	0.023*
MTX dosage (mg/w)		7.7 ± 4.3	6.7 ± 4.0	0.086*
ACPA (U/mL)		75.9 ± 141.9	332.1 ± 704.9	0.130*
RF (IU/mL)		126.4 ± 213.1	158.1 ± 261.4	0.718*
MMP-3 (ng/mL)		196.2 ± 234.4	321.2 ± 551.0	0.066*
TNF-α (pg/mL)		60.2 ± 176.1	73.3 ± 155.6	0.585*
IL-6 (pg/mL)		33.7 ± 81.6	7.7 ± 4.3	0.406*
SDAI		22.5 ± 13.4	32.1 ± 12.9	0.000*
HAQ-DI		0.39 ± 0.51	1.08 ± 0.54	0.000*
SDS		40.4 ± 9.9	43.5 ± 9.2	0.149*
HAM-D		5.0 ± 4.3	8.4 ± 5.0	0.004*
SF-36	Physical functioning	35.1 ± 15.1	14.6± 15.6	0.000*
	Role function	35.3 ± 15.6	22.6 ± 13.9	0.000*
	Pain	37.0 ± 9.4	30.9 ± 7.3	0.002*
	General health perception	40.1 ± 8.5	34.2 ± 8.4	0.001*
	Fatigue	45.2 ± 10.8	37.6 ± 10.7	0.003*
	Social functioning	42.6 ± 14.1	32.6 ± 14.0	0.000*
	Role function(emotional)	41.9 ± 14.9	28.0 ± 16.4	0.000*
	Mental health	47.3 ± 10.8	41.8 ± 11.1	0.013*

Mean ± standard deviation value are used.

MTX: methotrexate, ACPA: anti-cyclic citrullinated peptides antibody, RF: rheumatoid factor, MMP-3: matrix metalloproteinase 3, TNF-α: tumor necrosis factor-α IL-6: interleukin-6, SDAI: Simplified Disease Activity Index, HAQ-DI: health assessment questionnaire disability index, SDS: Self-rating Depression Scale, HAM-D: Hamilton Depression Rating Scale, SF-36: short form-36

*analysis using Mann-Whitney U test.

**analysis using chi-squared test for independence test.